▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Keith Speights

TMFFishBiz

Keith Speights has been a contributing writer and analyst for The Motley Fool since 2012. Prior to The Motley Fool, Speights was CEO of a healthcare technology company; vice president of a healthcare software company; director of operations for a health insurer; and a technology consultant. He holds a B.S. in Industrial Engineering from Mississippi State University.

Recent Articles by Keith Speights

Dollar signs on board behind man using laptop

Jun 23, 2021 by Keith Speights

Ditch Dogecoin: These 3 Stocks Could Double Your Money

The path to a twofold or greater return is straightforward for each of these stocks.

EU flag with syringe

Jun 22, 2021 by Keith Speights

Why Moderna Stock Jumped 6% Today

The company announced another big European supply deal.

Scientist in lab looking through microscope

Jun 22, 2021 by Keith Speights

Why Atossa Therapeutics Stock Is Jumping Today

There are two likely drivers behind the biotech's share price surge.

Warning sign

Jun 22, 2021 by Keith Speights

Why Clover Health Stock Is Soaring Today

The company cautioned about a short squeeze, but investors seem to be shrugging off the warning.

GAAP blocks

Jun 22, 2021 by Keith Speights

Why It's a Big Deal for Cresco Labs to Report GAAP Financial Results

The move underscores which investors Cresco is trying to attract.

2 green jigsaw puzzle pieces

Jun 22, 2021 by Keith Speights

Why Trulieve's Acquisition of Harvest Health Could Pay Off Big-Time

The Florida medical cannabis giant is expanding its focus tremendously with this deal.

Binoculars- man seeing charts trending down

Jun 22, 2021 by Keith Speights

2 Robinhood Stocks Wall Street Predicts Will Plunge More Than 25%

But are analysts' pessimistic predictions likely to be right?

Vaccine bottles forming a dollar sign

Jun 22, 2021 by Keith Speights

Why Moderna Just Booked Another $3 Billion in Vaccine Orders and No One Cared

Investors seemed to yawn over a really big new deal for the vaccine maker.

Alzheimer's disease

Jun 21, 2021 by Keith Speights

Why Cassava Sciences Stock Soared Today

Investors applauded the company's update on its clinical programs.

Vaccine being given to teen boy

Jun 21, 2021 by Keith Speights

Why BioNTech Stock Is Rising Today

The biotech received some good news, but its gain probably was due to another reason.

Cannabis leaf on $100 bills

Jun 21, 2021 by Keith Speights

3 Under-the-Radar Cannabis Stocks to Buy Right Now

They don't receive the attention that some pot stocks do, but these U.S. stocks could be huge winners.

3 $100 bills on beach at dawn

Jun 21, 2021 by Keith Speights

My 3 Highest-Conviction Stocks This Summer

There are good reasons this Fool is super-bullish about these picks.

pharmacists filling pills

Jun 22, 2021 by Keith Speights and Brian Orelli, PhD

Why Biogen Isn't a Buy After Its Alzheimer's Drug Approval

Here's one longtime healthcare expert's perspective.

gettyimages-1230743370-594x594

Jun 22, 2021 by Keith Speights and Brian Orelli, PhD

Is Johnson & Johnson Now a Has-Been in the COVID Vaccine Market?

In some ways, yes.

Alzheimer's disease

Jun 22, 2021 by Keith Speights and Brian Orelli, PhD

Could Biogen's Stunning Alzheimer's Drug Victory Only Be Temporary?

In theory, yes. Realistically, probably not.

Warren Buffett (TMF photo)

Jun 20, 2021 by Keith Speights

This Is Warren Buffett's Best Dividend Stock by Far

There's a lot to like with this Buffett stock.

Young woman on beach with laptop

Jun 20, 2021 by Keith Speights

3 Great Candidates to Be the Summer's Hottest Meme Stocks

They're beaten down. Short-sellers have piled on. In other words, they're ideal meme stocks.

pharmacists speaking with client at counter

Jun 25, 2021 by Keith Speights and Brian Orelli, PhD

Biogen's Alzheimer's Drug Deals With CVS and Cigna: What Investors Should Know

One of these agreements could be more important than the other.

physician holding a pill

Jun 25, 2021 by Keith Speights and Brian Orelli, PhD

2 Stocks That Could Be Winners in Alzheimer's Disease Along With Biogen

One is Biogen's partner. The other is a potential rival.

COVID-19 vaccine vials

Jun 25, 2021 by Keith Speights and Brian Orelli, PhD

What to Make of the CDC's Latest Efficacy Data on Pfizer's and Moderna's COVID Vaccines

The news continued to be good for mRNA vaccines.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services